Navigation Links
Optimer Announces that the U.S. Food and Drug Administration's Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Date:4/5/2011

effective as vancomycin in clinical cure, and was superior to vancomycin in global cure, defined as cure without a recurrence after 4 weeks of therapy. The advisory committee referred to the global cure outcome as 30-day resolution, which we believe is indicative of DIFICID's benefit in reducing recurrences," said Sherwood Gorbach, M.D., Optimer's Chief Medical Officer. "While the advisory committee vote was split on how best to describe the recurrence benefit, the committee members overwhelmingly recognized that DIFICID at 30 days was superior to vancomycin. We appreciated the committee's discussion and look forward to working with the FDA as it considers our DIFICID NDA."

The AIDAC based its decision in part on the review of clinical evidence from the two largest, comparative Phase 3 clinical trials ever conducted against vancomycin in CDI. These multi-center, randomized, double-blind trials enrolled a total of 1,164 adults with confirmed CDI, who received either DIFICID (200 mg q12h) or vancomycin (125 mg q6h), the only FDA-approved product for the treatment of CDI. The objective of both studies was to show that a 10-day course of DIFICID was at least as efficacious (non-inferior) and safe as a 10-day course of vancomycin for the treatment of CDI. In both studies, DIFICID demonstrated a statistically significant reduction in the rate of recurrence compared with patients treated with vancomycin, reducing CDI recurrences by 47 percent, and was statistically superior to vancomycin in global cure rate (clinical cure without disease recurrence within four weeks). In addition, DIFICID met the primary endpoint of non-inferiority of clinical cure (defined as patients requiring no further CDI therapy two days after completion of study medication) compared to vancomycin.

DIFICID was safe and well tolerated in both studies, showing a similar incidence of treatment-related adverse events when compared to vancomycin.

Scheduled Conference Call


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... SAN DIEGO , Oct. 1, 2014  ResMed (NYSE: ... people sleep and the first company to design complete sleep ... to educate women about the importance of a good night,s ... initiative will challenge the myth that feeling tired is just ... to understand that sleep is a critical pillar of health, ...
(Date:10/1/2014)... -- NeuroCall, Inc., ("NeuroCall") announced today that it recently ... services. Dr. Ricardo Garcia-Rivera , Founder and Chief ... that our quality of service has been recognized by ... support and continuity of care to patients of our ... United States ." NeuroCall currently ...
(Date:10/1/2014)...  Varian Medical Systems (NYSE: VAR ) ... fourth quarter of fiscal year 2014 following the close ... news release will be followed by a teleconference available ... news release and a link to the conference call ... www.varian.com/investor .  To access the teleconference call and ...
Breaking Medicine Technology:ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3NeuroCall Awarded Joint Commission Accreditation 2Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
... Inc. (Nasdaq: ABAX ), a medical products company ... chairman and chief executive officer, will present at the RBC ... 10:00 a.m. ET. The conference will be held at the ... A live webcast of the presentation will be available to ...
... The Cystic Fibrosis Foundation and Vertex Pharmaceuticals announced today ... defective protein that causes cystic fibrosis, showed promising results in ... was designed to evaluate patients age 12 and up who ... G551D. The study included 161 patients who received at least ...
Cached Medicine Technology:Abaxis, Inc. to Present at RBC Capital Markets' Healthcare Conference 2Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation 2Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation 3
(Date:10/2/2014)... Norton HealthDay Reporter WEDNESDAY, Oct. ... the roses -- literally -- may face an increased risk of ... a study of over 3,000 older Americans, researchers found those who ... were more than three times as likely to die in the ... In fact, anosmia -- the inability to distinguish odors -- ...
(Date:10/2/2014)... at The University of Nottingham could lead to the ... A drug resulting from the research, published in the ... hope to sufferers of chronic pain conditions such as ... currently available. , The work, led by Dr Lucy ... collaboration with David Bates, Professor of Oncology in the ...
(Date:10/1/2014)... shown that more than 80 per cent of bowel ... study found that medicines called ,JAK inhibitors, halted tumour ... is present in more than 80 per cent of ... are in clinical trials, for diseases including rheumatoid arthritis, ... is the second-most common cancer in Australia with nearly ...
(Date:10/1/2014)... co-funded by the Engineering and Physical Sciences Research ... the UK,s vital industrial control systems which run, ... grid, and the rail network. , The ... hackers or malware infiltrating the systems behind our ... in Trustworthy Industrial Control Systems (RITICS), based at ...
(Date:10/1/2014)... the adage that encourages people to keep their "eyes ... comes to exercise. When walking, staying focused on a ... appear shorter and help people walk there faster, psychology ... to walking while looking around the environment naturally, offers ... , "People are less interested in exercise if physical ...
Breaking Medicine News(10 mins):Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Medical discovery first step on path to new painkillers 2Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
... novel study found that the use of Herceptin in advanced ... toxicity − nearly 28 percent of patients treated with ... lining is that much of the damage to the heart ... published online August 14 in the Journal of Clinical Oncology, ...
... OHSU Tinnitus Clinic and the School of Dentistry is ... their relationship with hearing loss//. Apparently the relationship has ... of the study leaders, said"Over the years, we have ... convinced that long-term exposure to sound from high-speed hand ...
... The three-hour open-heart surgery was performed on a 17 yr ... ,An eight-member team led by cardio thoracic surgeon ... suffering from an arterial septal, congenital defect on the 4th ... of TMCH said that the patient, S.Velumurugan's condition was stable ...
... from the US have shown that yellow plant pigments ... macular degeneration (AMD). ,The study conducted by the ... published in the Journal of Ophthalmology, states that carrots ... but brightly coloured yellow and green vegetables do have ...
... Most women who undergo surgery following an early pregnancy ... under general ,anesthesia//. However a new study has raised ... ,Early pregnancy failure - or EPF - occurs in ... with surgery typically haven't been performed in ,an office-based ...
... of a fourth drug to the usual three-drug HIV treatment ... did not reduce the HIV load// or the drug resistance, ... 16 issue of JAMA, a theme issue on HIV/AIDS. ... of Cornell University, New York, presented the findings of the ...
Cached Medicine News:Health News:Herceptin Use May Enhance Cardiac Toxicity, Study 2Health News:Herceptin Use May Enhance Cardiac Toxicity, Study 3Health News:Is There a Connection between Hearing loss and High-speed Dental Tools? 2Health News:Is There a Connection between Hearing loss and High-speed Dental Tools? 3Health News:Yellow Fruits And Vegetables Help In Fight Against Loss Of Eyesight 2Health News:Women Prefer Office Procedure during treatment of Early Pregnancy 2Health News:Women Prefer Office Procedure during treatment of Early Pregnancy 3Health News:Four-Drug AIDS Treatment Regimen Deemed Of No Use 2
AST (SGOT) R1 + R2. Automated analyzer test kits....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
The Midas II Stainer is an automated slide stainer designed for use in hematology and microbiology laboratories....
... TST 40 tissue stainer is an "assembly-line ... in histology and cytology laboratories. Programmable continuous ... stains big quantities of slides in short ... in combination with a continuous working principle ...
Medicine Products: